M
Markella Konstantinidou
Researcher at University of Groningen
Publications - 16
Citations - 541
Markella Konstantinidou is an academic researcher from University of Groningen. The author has contributed to research in topics: Isocyanide & Ugi reaction. The author has an hindex of 6, co-authored 16 publications receiving 288 citations. Previous affiliations of Markella Konstantinidou include Aristotle University of Thessaloniki.
Papers
More filters
Journal ArticleDOI
Covalent inhibitors: A rational approach to drug discovery
TL;DR: In this review, a brief historic overview of covalent inhibitors is provided and recent advances focusing on developments in the last decade are summarized.
Journal ArticleDOI
Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
Markella Konstantinidou,Tryfon Zarganes-Tzitzikas,Katarzyna Magiera-Mularz,Tad A. Holak,Tad A. Holak,Alexander Dömling +5 more
TL;DR: The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.
Journal ArticleDOI
PROTACs- a game-changing technology.
Markella Konstantinidou,Jingyao Li,Bidong Zhang,Zefeng Wang,Shabnam Shaabani,Frans ter Brake,Khaled Essa,Alexander Dömling +7 more
TL;DR: PROTACs have shown remarkable biological responses in challenging targets, including an unprecedented selectivity over protein family members and even efficacy starting from weak or unspecific binders, and are expected to soon become a new therapeutic category of drugs.
Journal ArticleDOI
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
Tryfon Zarganes-Tzitzikas,Markella Konstantinidou,Yongzhi Gao,Dobroslawa Krzemien,Krzysztof M. Zak,Grzegorz Dubin,Tad A. Holak,Alexander Dömling +7 more
TL;DR: The search for the magic bullet in cancer immunotherapies is ongoing since more than 100 years, but only recent clinical success of immune checkpoint directed antibodies significantly revived the fortunes of these drugs.
Journal ArticleDOI
The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
Markella Konstantinidou,Asmaa Oun,Pragya Pathak,Bidong Zhang,Zefeng Wang,Frans ter Brake,Amalia M. Dolga,Arjan Kortholt,Arjan Kortholt,Alexander Dömling +9 more
TL;DR: The rational design and synthetic methodologies towards proteolysis‐targeting chimeras (PROTACs) for the recently‐emerged target leucine‐rich repeat kinase 2 (LRRK2) are presented.